Rigel Pharma beats Q3 revenue estimates; lifts annual rev outlook

Rigel Pharmaceuticals

04/11/2025 21:16

Overview

Rigel Q3 2025 revenue of $69.5 mln beats analyst expectations

Net product sales grew 65% yr/yr, driven by TAVALISSE, GAVRETO, and REZLIDHIA

Company raises 2025 revenue guidance to $285-$290 mln due to strong performance

Outlook

Rigel raises 2025 total revenue guidance to $285-$290 mln, from $270-$280 mln

Company expects 2025 net product sales of $225-$230 mln

Rigel anticipates 2025 contract revenues of approximately $60 mln

Result Drivers

NET PRODUCT SALES - Net product sales increased by 65% yr/yr, driven by TAVALISSE, GAVRETO, and REZLIDHIA

R289 STUDY PROGRESS - Completed dose escalation phase and initiated dose expansion phase in R289 study for lower-risk MDS

CONTRACT REVENUES - Contract revenues from collaborations contributed $5.4 million, primarily from Grifols, Kissei, and Medison

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$69.50 mln
$61.87 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $29.50, about 3.9% below its November 3 closing price of $30.65

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nPn5lsg6Da

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)